title: Randomized trial of [131I] metuximab in treatment of hepatocellular carcinoma after percutaneous radiofrequency ablation.
abstract: To assess the efficacy of combining radioimmunoconjugate [(131)I] metuximab with radiofrequency ablation (RFA) in hepatocellular carcinoma (HCC) treatment compared with RFA alone, a single-center randomized controlled trial was conducted on 127 patients with Barcelona Clinic Liver Cancer staging system (BCLC) classifications of 0-B stage. Patients received either RFA followed by [(131)I] metuximab (n = 62) or RFA alone (n = 65). The primary outcome was overall tumor recurrence. Statistical tests were two-sided. The one- and two-year recurrence rates in the combination group were 31.8% and 58.5%, whereas those in the RFA group were 56.3% and 70.9%, respectively. The median time to overall tumor recurrence was 17 months in the combination group and 10 months in the RFA group (P = .03). The RFA-[(131)I] metuximab treatment showed a greater antirecurrence benefit than RFA in the metuximab target (ie, CD147)-positive subpopulation (P = .007). [(131)I] metuximab may yield prevention of tumor recurrence after RFA.
authors.affiliation: Cell Engineering Research Center and Department of Cell Biology, State Key Laboratory of Cancer Biology (HB, GN, YZ, XLW, JW, JX, DW, ZNC) and Department of Health Statistics (CC), Fourth Military Medical University, Xi'an, China; Oncology and Hepatobiliary Minimally Invasive Interventional Center, Beijing Youan Hospital, Capital Medical University, Beijing, China (JSZ, RL, CXH, BS, SCC); Radionuclide Diagnosis and Treatment Center, No. 401 Hospital of China Nuclear Industry, Beijing, China (XZ, HL); Tumor Minimally Invasive Therapy Division (WY, JL) and Department of Nuclear Medicine (YD), Hospital 307 of PLA, Beijing, China.
authors.forename: Huijie
authors.initials: H
authors.lastname: Bian
authors.affiliation: Cell Engineering Research Center and Department of Cell Biology, State Key Laboratory of Cancer Biology (HB, GN, YZ, XLW, JW, JX, DW, ZNC) and Department of Health Statistics (CC), Fourth Military Medical University, Xi'an, China; Oncology and Hepatobiliary Minimally Invasive Interventional Center, Beijing Youan Hospital, Capital Medical University, Beijing, China (JSZ, RL, CXH, BS, SCC); Radionuclide Diagnosis and Treatment Center, No. 401 Hospital of China Nuclear Industry, Beijing, China (XZ, HL); Tumor Minimally Invasive Therapy Division (WY, JL) and Department of Nuclear Medicine (YD), Hospital 307 of PLA, Beijing, China.
authors.forename: Jia-Sheng
authors.initials: JS
authors.lastname: Zheng
authors.affiliation: Cell Engineering Research Center and Department of Cell Biology, State Key Laboratory of Cancer Biology (HB, GN, YZ, XLW, JW, JX, DW, ZNC) and Department of Health Statistics (CC), Fourth Military Medical University, Xi'an, China; Oncology and Hepatobiliary Minimally Invasive Interventional Center, Beijing Youan Hospital, Capital Medical University, Beijing, China (JSZ, RL, CXH, BS, SCC); Radionuclide Diagnosis and Treatment Center, No. 401 Hospital of China Nuclear Industry, Beijing, China (XZ, HL); Tumor Minimally Invasive Therapy Division (WY, JL) and Department of Nuclear Medicine (YD), Hospital 307 of PLA, Beijing, China.
authors.forename: Gang
authors.initials: G
authors.lastname: Nan
authors.affiliation: Cell Engineering Research Center and Department of Cell Biology, State Key Laboratory of Cancer Biology (HB, GN, YZ, XLW, JW, JX, DW, ZNC) and Department of Health Statistics (CC), Fourth Military Medical University, Xi'an, China; Oncology and Hepatobiliary Minimally Invasive Interventional Center, Beijing Youan Hospital, Capital Medical University, Beijing, China (JSZ, RL, CXH, BS, SCC); Radionuclide Diagnosis and Treatment Center, No. 401 Hospital of China Nuclear Industry, Beijing, China (XZ, HL); Tumor Minimally Invasive Therapy Division (WY, JL) and Department of Nuclear Medicine (YD), Hospital 307 of PLA, Beijing, China.
authors.forename: Rui
authors.initials: R
authors.lastname: Li
authors.affiliation: Cell Engineering Research Center and Department of Cell Biology, State Key Laboratory of Cancer Biology (HB, GN, YZ, XLW, JW, JX, DW, ZNC) and Department of Health Statistics (CC), Fourth Military Medical University, Xi'an, China; Oncology and Hepatobiliary Minimally Invasive Interventional Center, Beijing Youan Hospital, Capital Medical University, Beijing, China (JSZ, RL, CXH, BS, SCC); Radionuclide Diagnosis and Treatment Center, No. 401 Hospital of China Nuclear Industry, Beijing, China (XZ, HL); Tumor Minimally Invasive Therapy Division (WY, JL) and Department of Nuclear Medicine (YD), Hospital 307 of PLA, Beijing, China.
authors.forename: Changsheng
authors.initials: C
authors.lastname: Chen
authors.affiliation: Cell Engineering Research Center and Department of Cell Biology, State Key Laboratory of Cancer Biology (HB, GN, YZ, XLW, JW, JX, DW, ZNC) and Department of Health Statistics (CC), Fourth Military Medical University, Xi'an, China; Oncology and Hepatobiliary Minimally Invasive Interventional Center, Beijing Youan Hospital, Capital Medical University, Beijing, China (JSZ, RL, CXH, BS, SCC); Radionuclide Diagnosis and Treatment Center, No. 401 Hospital of China Nuclear Industry, Beijing, China (XZ, HL); Tumor Minimally Invasive Therapy Division (WY, JL) and Department of Nuclear Medicine (YD), Hospital 307 of PLA, Beijing, China.
authors.forename: Cai-Xia
authors.initials: CX
authors.lastname: Hu
authors.affiliation: Cell Engineering Research Center and Department of Cell Biology, State Key Laboratory of Cancer Biology (HB, GN, YZ, XLW, JW, JX, DW, ZNC) and Department of Health Statistics (CC), Fourth Military Medical University, Xi'an, China; Oncology and Hepatobiliary Minimally Invasive Interventional Center, Beijing Youan Hospital, Capital Medical University, Beijing, China (JSZ, RL, CXH, BS, SCC); Radionuclide Diagnosis and Treatment Center, No. 401 Hospital of China Nuclear Industry, Beijing, China (XZ, HL); Tumor Minimally Invasive Therapy Division (WY, JL) and Department of Nuclear Medicine (YD), Hospital 307 of PLA, Beijing, China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Cell Engineering Research Center and Department of Cell Biology, State Key Laboratory of Cancer Biology (HB, GN, YZ, XLW, JW, JX, DW, ZNC) and Department of Health Statistics (CC), Fourth Military Medical University, Xi'an, China; Oncology and Hepatobiliary Minimally Invasive Interventional Center, Beijing Youan Hospital, Capital Medical University, Beijing, China (JSZ, RL, CXH, BS, SCC); Radionuclide Diagnosis and Treatment Center, No. 401 Hospital of China Nuclear Industry, Beijing, China (XZ, HL); Tumor Minimally Invasive Therapy Division (WY, JL) and Department of Nuclear Medicine (YD), Hospital 307 of PLA, Beijing, China.
authors.forename: Bin
authors.initials: B
authors.lastname: Sun
authors.affiliation: Cell Engineering Research Center and Department of Cell Biology, State Key Laboratory of Cancer Biology (HB, GN, YZ, XLW, JW, JX, DW, ZNC) and Department of Health Statistics (CC), Fourth Military Medical University, Xi'an, China; Oncology and Hepatobiliary Minimally Invasive Interventional Center, Beijing Youan Hospital, Capital Medical University, Beijing, China (JSZ, RL, CXH, BS, SCC); Radionuclide Diagnosis and Treatment Center, No. 401 Hospital of China Nuclear Industry, Beijing, China (XZ, HL); Tumor Minimally Invasive Therapy Division (WY, JL) and Department of Nuclear Medicine (YD), Hospital 307 of PLA, Beijing, China.
authors.forename: Xi-Long
authors.initials: XL
authors.lastname: Wang
authors.affiliation: Cell Engineering Research Center and Department of Cell Biology, State Key Laboratory of Cancer Biology (HB, GN, YZ, XLW, JW, JX, DW, ZNC) and Department of Health Statistics (CC), Fourth Military Medical University, Xi'an, China; Oncology and Hepatobiliary Minimally Invasive Interventional Center, Beijing Youan Hospital, Capital Medical University, Beijing, China (JSZ, RL, CXH, BS, SCC); Radionuclide Diagnosis and Treatment Center, No. 401 Hospital of China Nuclear Industry, Beijing, China (XZ, HL); Tumor Minimally Invasive Therapy Division (WY, JL) and Department of Nuclear Medicine (YD), Hospital 307 of PLA, Beijing, China.
authors.forename: Shi-Chang
authors.initials: SC
authors.lastname: Cui
authors.affiliation: Cell Engineering Research Center and Department of Cell Biology, State Key Laboratory of Cancer Biology (HB, GN, YZ, XLW, JW, JX, DW, ZNC) and Department of Health Statistics (CC), Fourth Military Medical University, Xi'an, China; Oncology and Hepatobiliary Minimally Invasive Interventional Center, Beijing Youan Hospital, Capital Medical University, Beijing, China (JSZ, RL, CXH, BS, SCC); Radionuclide Diagnosis and Treatment Center, No. 401 Hospital of China Nuclear Industry, Beijing, China (XZ, HL); Tumor Minimally Invasive Therapy Division (WY, JL) and Department of Nuclear Medicine (YD), Hospital 307 of PLA, Beijing, China.
authors.forename: Jiao
authors.initials: J
authors.lastname: Wu
authors.affiliation: Cell Engineering Research Center and Department of Cell Biology, State Key Laboratory of Cancer Biology (HB, GN, YZ, XLW, JW, JX, DW, ZNC) and Department of Health Statistics (CC), Fourth Military Medical University, Xi'an, China; Oncology and Hepatobiliary Minimally Invasive Interventional Center, Beijing Youan Hospital, Capital Medical University, Beijing, China (JSZ, RL, CXH, BS, SCC); Radionuclide Diagnosis and Treatment Center, No. 401 Hospital of China Nuclear Industry, Beijing, China (XZ, HL); Tumor Minimally Invasive Therapy Division (WY, JL) and Department of Nuclear Medicine (YD), Hospital 307 of PLA, Beijing, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Xu
authors.affiliation: Cell Engineering Research Center and Department of Cell Biology, State Key Laboratory of Cancer Biology (HB, GN, YZ, XLW, JW, JX, DW, ZNC) and Department of Health Statistics (CC), Fourth Military Medical University, Xi'an, China; Oncology and Hepatobiliary Minimally Invasive Interventional Center, Beijing Youan Hospital, Capital Medical University, Beijing, China (JSZ, RL, CXH, BS, SCC); Radionuclide Diagnosis and Treatment Center, No. 401 Hospital of China Nuclear Industry, Beijing, China (XZ, HL); Tumor Minimally Invasive Therapy Division (WY, JL) and Department of Nuclear Medicine (YD), Hospital 307 of PLA, Beijing, China.
authors.forename: Ding
authors.initials: D
authors.lastname: Wei
authors.affiliation: Cell Engineering Research Center and Department of Cell Biology, State Key Laboratory of Cancer Biology (HB, GN, YZ, XLW, JW, JX, DW, ZNC) and Department of Health Statistics (CC), Fourth Military Medical University, Xi'an, China; Oncology and Hepatobiliary Minimally Invasive Interventional Center, Beijing Youan Hospital, Capital Medical University, Beijing, China (JSZ, RL, CXH, BS, SCC); Radionuclide Diagnosis and Treatment Center, No. 401 Hospital of China Nuclear Industry, Beijing, China (XZ, HL); Tumor Minimally Invasive Therapy Division (WY, JL) and Department of Nuclear Medicine (YD), Hospital 307 of PLA, Beijing, China.
authors.forename: Xiaoyong
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Cell Engineering Research Center and Department of Cell Biology, State Key Laboratory of Cancer Biology (HB, GN, YZ, XLW, JW, JX, DW, ZNC) and Department of Health Statistics (CC), Fourth Military Medical University, Xi'an, China; Oncology and Hepatobiliary Minimally Invasive Interventional Center, Beijing Youan Hospital, Capital Medical University, Beijing, China (JSZ, RL, CXH, BS, SCC); Radionuclide Diagnosis and Treatment Center, No. 401 Hospital of China Nuclear Industry, Beijing, China (XZ, HL); Tumor Minimally Invasive Therapy Division (WY, JL) and Department of Nuclear Medicine (YD), Hospital 307 of PLA, Beijing, China.
authors.forename: Haichun
authors.initials: H
authors.lastname: Liu
authors.affiliation: Cell Engineering Research Center and Department of Cell Biology, State Key Laboratory of Cancer Biology (HB, GN, YZ, XLW, JW, JX, DW, ZNC) and Department of Health Statistics (CC), Fourth Military Medical University, Xi'an, China; Oncology and Hepatobiliary Minimally Invasive Interventional Center, Beijing Youan Hospital, Capital Medical University, Beijing, China (JSZ, RL, CXH, BS, SCC); Radionuclide Diagnosis and Treatment Center, No. 401 Hospital of China Nuclear Industry, Beijing, China (XZ, HL); Tumor Minimally Invasive Therapy Division (WY, JL) and Department of Nuclear Medicine (YD), Hospital 307 of PLA, Beijing, China.
authors.forename: Wuwei
authors.initials: W
authors.lastname: Yang
authors.affiliation: Cell Engineering Research Center and Department of Cell Biology, State Key Laboratory of Cancer Biology (HB, GN, YZ, XLW, JW, JX, DW, ZNC) and Department of Health Statistics (CC), Fourth Military Medical University, Xi'an, China; Oncology and Hepatobiliary Minimally Invasive Interventional Center, Beijing Youan Hospital, Capital Medical University, Beijing, China (JSZ, RL, CXH, BS, SCC); Radionuclide Diagnosis and Treatment Center, No. 401 Hospital of China Nuclear Industry, Beijing, China (XZ, HL); Tumor Minimally Invasive Therapy Division (WY, JL) and Department of Nuclear Medicine (YD), Hospital 307 of PLA, Beijing, China.
authors.forename: Yong
authors.initials: Y
authors.lastname: Ding
authors.affiliation: Cell Engineering Research Center and Department of Cell Biology, State Key Laboratory of Cancer Biology (HB, GN, YZ, XLW, JW, JX, DW, ZNC) and Department of Health Statistics (CC), Fourth Military Medical University, Xi'an, China; Oncology and Hepatobiliary Minimally Invasive Interventional Center, Beijing Youan Hospital, Capital Medical University, Beijing, China (JSZ, RL, CXH, BS, SCC); Radionuclide Diagnosis and Treatment Center, No. 401 Hospital of China Nuclear Industry, Beijing, China (XZ, HL); Tumor Minimally Invasive Therapy Division (WY, JL) and Department of Nuclear Medicine (YD), Hospital 307 of PLA, Beijing, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Li
authors.affiliation: Cell Engineering Research Center and Department of Cell Biology, State Key Laboratory of Cancer Biology (HB, GN, YZ, XLW, JW, JX, DW, ZNC) and Department of Health Statistics (CC), Fourth Military Medical University, Xi'an, China; Oncology and Hepatobiliary Minimally Invasive Interventional Center, Beijing Youan Hospital, Capital Medical University, Beijing, China (JSZ, RL, CXH, BS, SCC); Radionuclide Diagnosis and Treatment Center, No. 401 Hospital of China Nuclear Industry, Beijing, China (XZ, HL); Tumor Minimally Invasive Therapy Division (WY, JL) and Department of Nuclear Medicine (YD), Hospital 307 of PLA, Beijing, China. znchen@fmmu.edu.cn zhengjiasheng6@163.com.
authors.forename: Zhi-Nan
authors.initials: ZN
authors.lastname: Chen
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D017115:Catheter Ablation; D005260:Female; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D009367:Neoplasm Staging; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D018796:Immunoconjugates; D007457:Iodine Radioisotopes; C511207:metuximab